Skip to main content Help with accessibility Skip to main navigation

UPADACITINIB prolonged-release tablets (Rinvoq®▼) for non-radiographic axial spondyloarthritis

CCG Approval Status:

Date Added: 25 - Oct - 2022
Body System:
Grey

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of UPADACITINIB prolonged-release tablets (Rinvoq®▼) for non-radiographic axial spondyloarthritis.